Necrolytic migratory erythema associated with alteration from predominantly gastrin-secreting to predominantly glucagon- secreting pancreatic neuroendocrine tumor

Johnson SM, Smoller BR, Lamps LW, Horn TD. Necrolytic migratory erythema as the only presenting sign of a glucagonoma. J Am Acad Dermatol 2003; 49: 325–8. Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012; 47: 941–60. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol 1998; 38: 866–73. Technau K, Renkl A, Norgauer J, Ziemer M. Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma. Eur J Dermatol 2005; 15: 110–2. Tseng HC, Liu CT, Ho JC, Lin SH. Necrolytic migratory erythema and glucagonoma rising from pancreatic head. Pancreatology 2013; 13: 455–7. Ohneda A, Otsuki M, Fujiya H, Yaginuma N, Kokubo T, Ohtani H. A malignant insulinoma transformed into a glucagonoma syndrome. Diabetes 1979; 28: 962–9. Kobayashi M, Kawa S, Kobayashi M, Imai Y, Sodeyama T, Kiyosawa K. Malignant insulinoma presenting a non-functioning metastatic liver tumor 14 years after resection of the primary tumor. J Gastroenterol 1998; 33: 891–4. Stephen AE, Hodin RA. Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am 2006; 15: 497–510.